These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 16290123)

  • 1. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association between ACE gene polymorphism and therapeutic responsiveness of ACEI in diabetic nephropathy].
    Wang L; Pan CY; Hu W
    Zhonghua Yi Xue Za Zhi; 1998 May; 78(5):372-4. PubMed ID: 10923445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of gene polymorphisms in the renin-angiotensin system to macroangiopathy in patients with diabetic nephropathy.
    Wong TY; Szeto CC; Chow KM; Chan JC; Li PK
    Am J Kidney Dis; 2001 Jul; 38(1):9-17. PubMed ID: 11431175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between I/D polymorphism of angiotensin I converting enzyme gene and microvascular complications in type 2 diabetic patients].
    Moleda P; Majkowska L; Safranow K; Adler G; Goracy I
    Przegl Lek; 2007; 64(3):134-9. PubMed ID: 17941464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin converting enzyme (ACE) gene polymorphism in a diabetic cohort and diabetic nephropathy].
    Levinson O; Oren S; Yagil C; Sapojnikov M; Wechsler A; Bloch R; Yagil Y
    Harefuah; 1999 May; 136(10):768-73, 843. PubMed ID: 10955109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arteriovenous fistula patency associated with angiotensin-converting enzyme I/D polymorphism and ACE inhibition or AT1 receptor blockade.
    Moon JY; Jeong KH; Paik SS; Han JJ; Lee SH; Lee TW; Ihm CG; Kim MJ; Chung JH
    Nephron Clin Pract; 2009; 111(2):c110-6. PubMed ID: 19142023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition.
    Langham RG; Kelly DJ; Gow RM; Zhang Y; Cordonnier DJ; Pinel N; Zaoui P; Gilbert RE
    Diabetes Care; 2006 Dec; 29(12):2670-5. PubMed ID: 17130203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
    Gulec M; Caliskaner Z; Tunca Y; Ozturk S; Bozoglu E; Gul D; Erel F; Kartal O; Karaayvaz M
    Allergol Immunopathol (Madr); 2008; 36(3):134-40. PubMed ID: 18680700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene polymorphism of the renin-angiotensin system and progression of diabetic nephropathy.
    Orisio S
    J Nephrol; 1999; 12(1):9-17. PubMed ID: 10202997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the angiotensinogen M235T and angiotensin-converting enzyme insertion/deletion gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy.
    Eroglu Z; Cetinkalp S; Erdogan M; Kosova B; Karadeniz M; Kutukculer A; Gunduz C; Tetik A; Topcuoglu N; Ozgen AG; Tuzun M
    J Diabetes Complications; 2008; 22(3):186-90. PubMed ID: 18413162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms.
    Lee YJ; Jang HR; Kim SG; Chae DW; Do JY; Lee JE; Huh W; Kim DJ; Oh HY; Kim YG
    Nephrology (Carlton); 2011 Jul; 16(5):502-10. PubMed ID: 21303424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.